Sanofi, Lonza to Invest CHF290 Million in New Plant in Switzerland
February 27 2017 - 2:20AM
Dow Jones News
By Inti Landauro
PARIS--French pharmaceutical giant Sanofi SA (SAN.FR) and Swiss
rival Lonza Group AG (LOON.EB) will invest 290 million Swiss francs
($287.8 million) in a new biologics production plant in the town of
Visp in Switzerland.
"The strategic partnership enables Sanofi to react quickly to
fluctuations in demand in a short time frame, reinforcing their
capability to launch high-quality, next-generation biologic
medicines and ensure consistent access for patients," the firms
said in a joint statement.
Each company will invest 50% in the project, they said.
Sanofi said about 60% of the new drugs it develops are made up
of biologics, including monoclonal antibodies dedicated to key
diseases such as cardiovascular, immunology and inflammation,
neufology and oncology.
Large pharmaceutical firms like Sanofi are scrambling to get new
drugs on the market to replace several best-sellers whose patents
have entered or are soon entering public domain.
Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
February 27, 2017 02:05 ET (07:05 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Apr 2023 to Apr 2024
